September 30, 2020 -- CRB has created SlateXpace, a multimodal manufacturing facility solution to support complex therapeutic product pipelines.
SlateXpace provides flexibility, speed to market, and budget control to allow companies to quickly deliver multiple therapies to patients, according to the company. The suite-based platform manages every aspect of advanced therapy medicinal product (ATMP) manufacturing, from facility fabrication and delivery, equipment selection and installation, to start-up, qualification and operator training.
Using SlateXpace, a product can be run in one modality, then after decontamination, users can swap out single-use and mobile equipment and run a new batch in the same space -- in a different modality -- within a few weeks. Modalities that are currently supported by the platform include vaccines, monoclonal antibodies, viral vectors, plasmids, allogeneic cell therapies, and autologous cell therapies.
Copyright © 2020 scienceboard.net